Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Bullish +75

Moderna’s combo flu-COVID vaccine receives European authorization - CIDRAP

🩸 Moderna's first combination seasonal flu-COVID vaccine, mCombriax, received marketing authorization from the European Commission.

💉 The approval follows a positive review by the European Medicines Agency’s Committee for Medicinal Products for Human Use.

🗣️ Moderna CEO Stephane Bancel stated the single-dose vaccine aims to simplify immunization and strengthen healthcare system resilience in Europe.

🧬 mCombriax builds on Moderna's existing COVID-19 vaccine (mNexspike) and investigational flu vaccine (mRNA-1010), both widely reviewed globally.

💪 Phase 3 trials showed significant immune responses against three influenza strains and SARS-CoV-2 in adults aged 50 to 64 and 65+.

⚠️ No major safety concerns or adverse events were observed during the phase 3 trial period.

🌍 The marketing authorization applies to all 27 EU member states plus Iceland, Liechtenstein, and Norway.

Bullish Signals
  • Moderna's mCombriax combination flu-COVID vaccine has received marketing authorization from the European Commission after a positive review by the European Medicines Agency's Committee for Medicinal Products for Human Use.
  • The vaccine performed well in a phase 3 trial, eliciting statistically significant higher immune responses against three influenza virus strains and SARS-CoV-2 in adults aged 50 to 64 years and 65 years and older.
  • Moderna CEO Stephane Bancel stated the combination vaccine aims to simplify immunization for high-risk adults while strengthening healthcare system resilience across Europe.
  • The marketing authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.
  • No major safety concerns or adverse events were observed in the phase 3 trial of mCombriax.
Risk Factors
  • CDC blocks publication of a report showing COVID vaccine efficacy, raising concerns about transparency and potential suppression of critical data.
  • Paxlovid trial results show the drug does not reduce hospitalization or death rates in vaccinated high-risk outpatients, limiting its efficacy for this demographic.
  • RFK Jr is holding up distribution of $600 million in vaccines to foreign nations, according to a report.
  • In hearings, RFK Jr claims no responsibility for measles spread despite ongoing concerns about the virus.
  • Hegseth removes flu vaccination requirement for US troops by calling mandates overly broad, potentially reducing herd immunity levels.
  • Seven in 10 people surveyed hold at least one view against medical science, indicating a significant misinformation challenge to public health initiatives.
  • Wild bird detections have dropped to just 13 notices from APHIS in the past 10 days, suggesting shifting epidemiological patterns that complicate tracking.
  • Eleven more marine mammals confirmed to have H5N1 avian flu in California brings the total to 58, with 57 sea lions and one otter affected.
Full Analysis
Moderna's mRNA-1283-based combination vaccine, mCombriax, has received marketing authorization from the European Commission for use in preventing seasonal influenza and COVID-19. This decision follows a positive review by the European Medicines Agency's Committee for Medicinal Products for Human Use and builds on the company's earlier development of its standalone mRNA-1010 influenza vaccine candidate. CEO Stephane Bancel highlighted that the single-dose combination aims to simplify immunization, particularly for high-risk adults, while strengthening European healthcare resilience. The authorization is valid across all 27 EU member states plus Iceland, Liechtenstein, and Norway. In phase 3 trials conducted among adults aged 50 to 64 and those 65 and older, the single dose of mCombriax elicited statistically significant immune responses against three influenza strains—A/H1N1, A/H3N2, and B/Victoria—as well as SARS-CoV-2. The company reported no major safety concerns or adverse events during the trial period. The vaccine's development relied on Moderna's previous COVID-19 vaccine technology, mNexspike, demonstrating the platform's adaptability for multiple respiratory pathogens. Outside of this primary announcement, global flu activity remains a focus with significant H5N1 avian flu detections in California marine mammals, including 58 confirmed cases involving 57 sea lions and one otter across four counties. Meanwhile, USDA reports 28 new commercial poultry outbreaks in the Midwest and other regions in recent weeks affecting roughly 700,000 birds, with three bald eagles also testing positive for the virus in the United States. These developments underscore ongoing challenges in avian influenza surveillance and public health response as health systems evaluate novel combination vaccines against emerging viral threats.